Bionomics Limited |
BNOX |
0% | -80% | -67% | -63% | 0% |
Immix Biopharma Inc. |
IMMX |
5% | -68% | 202% | -36% | 0% |
Genenta Science S.p.A. |
GNTA |
-3% | -3% | -16% | -51% | 0% |
AN2 Therapeutics Inc. |
ANTX |
3% | -93% | 115% | 0% | 0% |
Akanda Corp. |
AKAN |
0% | 0% | -5% | 0% | 0% |
Akanda Corp. |
AKAN |
0% | 0% | -5% | 0% | 0% |
Blue Water Vaccines Inc. |
BWV |
0% | -32% | -82% | 0% | 0% |
Meihua International Medical Technologies Co. Ltd |
MHUA |
3% | -76% | -82% | 0% | 0% |
ARCELLX Inc. |
ACLX |
3% | 38% | 79% | 0% | 0% |
Nuvectis Pharma Inc. |
NVCT |
2% | -35% | 11% | 0% | 0% |
Hillstream Biopharma Inc. |
HILS |
0% | 0% | -54% | 0% | 0% |
Amylyx Pharmaceuticals Inc. |
AMLX |
10% | -74% | -60% | 0% | 0% |
CinCor Pharma Inc. |
CINC |
0% | 0% | 136% | 0% | 0% |
Vigil Neuroscience Inc. |
VIGL |
9% | -50% | -73% | 0% | 0% |
Journey Medical Corporation |
DERM |
9% | -32% | 200% | -64% | 0% |
Vaxxinity Inc. |
VAXX |
0% | -74% | -39% | -75% | 0% |
IO Biotech Inc. |
IOBT |
-1% | -51% | -18% | -64% | 0% |
Evotec SE |
EVO |
7% | -64% | 44% | -66% | -68% |
MDxHEALTH SA |
MDXH |
0% | 0% | -45% | -40% | 0% |
LianBio |
LIAN |
0% | -93% | 173% | -73% | 0% |
Airsculpt Technologies Inc. |
AIRS |
13% | -31% | 102% | -78% | 0% |
Aura Biosciences Inc. |
AURA |
2% | -7% | -16% | -38% | 0% |
Entrada Therapeutics Inc. |
TRDA |
6% | 15% | -21% | 11% | 0% |
Xilio Therapeutics Inc. |
XLO |
11% | 78% | -80% | -83% | 0% |
Ventyx Biosciences Inc. |
VTYX |
13% | -11% | -92% | 65% | 0% |
Context Therapeutics Inc. |
CNTX |
18% | 0% | 0% | -69% | 0% |
MiNK Therapeutics Inc. |
INKT |
29% | -35% | -58% | -42% | 0% |
Lucid Diagnostics Inc. |
LUCD |
-2% | -42% | 4% | -75% | 0% |
Cognition Therapeutics Inc. |
CGTX |
7% | -62% | -12% | -67% | 0% |
IsoPlexis Corp. |
ISO |
0% | 0% | -51% | -83% | 0% |
Pyxis Oncology Inc. |
PYXS |
8% | -13% | 43% | -89% | 0% |
THESEUS Pharmaceuticals Inc. |
THRX |
0% | 0% | -19% | -61% | 0% |
Exscientia plc |
EXAI |
0% | -19% | 20% | -73% | 0% |
CUE Health Inc. |
HLTH |
0% | -10% | -92% | -85% | 0% |
DICE Therapeutics Inc. |
DICE |
0% | 0% | 52% | 24% | 0% |
Tyra Biosciences Inc. |
TYRA |
12% | 0% | 82% | -45% | 0% |
Eliem Therapeutics Inc. |
ELYM |
24% | -33% | -25% | -66% | 0% |
Acumen Pharmaceuticals Inc. |
ABOS |
10% | -55% | -29% | -20% | 0% |
Adagio Therapeutics Inc. |
ADGI |
0% | 0% | 0% | -51% | 0% |
Immuneering Corp. |
IMRX |
7% | -70% | 52% | -70% | 0% |
IN8bio Inc. |
INAB |
18% | 0% | 0% | -46% | 0% |
Omega Therapeutics Inc. |
OMGA |
11% | -75% | -47% | -50% | 0% |
Rani Therapeutics Holdings Inc. |
RANI |
12% | -59% | -44% | -64% | 0% |
Tenaya Therapeutics Inc. |
TNYA |
6% | -56% | 61% | -89% | 0% |
Icosavax Inc. |
ICVX |
0% | -3% | 98% | -65% | 0% |
Nuvalent Inc. |
NUVL |
3% | 6% | 147% | 56% | 0% |
Rallybio Corp. |
RLYB |
2% | -59% | -64% | -31% | 0% |
Candel Therapeutics Inc. |
CADL |
6% | 490% | -18% | -77% | 0% |
Cytek BioSciences Inc. |
CTKB |
5% | -29% | -11% | -37% | 0% |
Sophia Genetics SA. |
SOPH |
10% | -37% | 129% | -85% | 0% |
HCW Biologics Inc. |
HCWB |
3% | -65% | -36% | -17% | 0% |
Erasca Inc. |
ERAS |
9% | 18% | -51% | -72% | 0% |
Imago BioSciences Inc. |
IMGO |
0% | 0% | 0% | 52% | 0% |
Regencell Bioscience Holdings Limited |
RGC |
1% | -46% | -66% | -16% | 0% |
Stevanato Group S.p.A. |
STVN |
7% | -19% | 52% | -20% | 0% |
TScan Therapeutics Inc. |
TCRX |
0% | -48% | 258% | -64% | 0% |
Rapid Micro Biosystems Inc. |
RPID |
13% | 22% | -35% | -89% | 0% |
Sera Prognostics INC. |
SERA |
-1% | 36% | 386% | -82% | 0% |
Sight Sciences Inc. |
SGHT |
-4% | -29% | -58% | -31% | 0% |
Transcode Therapeutics Inc. |
RNAZ |
0% | 0% | -60% | -73% | 0% |
Aerovate Therapeutics Inc. |
AVTE |
1% | -88% | -23% | 149% | 0% |
Acurx Pharmaceuticals LLC |
ACXP |
7% | -79% | -4% | -10% | 0% |
Alpha Teknova Inc. |
TKNO |
4% | 123% | -34% | -73% | 0% |
Elevation Oncology Inc. |
ELEV |
18% | 5% | -43% | -84% | 0% |
GH Research PLC |
GHRS |
30% | 20% | -40% | -57% | 0% |
Graphite Bio Inc. |
GRPH |
0% | 21% | -21% | -73% | 0% |
Bright Health Group Inc. |
BHG |
0% | 0% | -68% | -82% | 0% |
Miromatrix Medical Inc. |
MIRO |
0% | 0% | 13% | -36% | 0% |
Monte Rosa Therapeutics Inc. |
GLUE |
3% | 23% | -26% | -63% | 0% |
Ambrx Biopharma Inc. |
AMAM |
0% | 0% | 468% | -75% | 0% |
ATAI Life Sciences B.V. |
ATA |
0% | 0% | 0% | 4% | 0% |
Century Therapeutics Inc. |
IPSC |
9% | -70% | -35% | -68% | 0% |
Codex DNA Inc. |
DNAY |
0% | -22% | -68% | -88% | 0% |
Cyteir Therapeutics Inc. |
CYT |
0% | -1% | 84% | -85% | 0% |
Femasys Inc. |
FEMY |
4% | 10% | 8% | -77% | 0% |
iSpecimen Inc. |
ISPC |
0% | -45% | -64% | -82% | 0% |
Lyell Immunopharma Inc. |
LYEL |
8% | -67% | -44% | -56% | 0% |
Verve Therapeutics Inc. |
VERV |
11% | -60% | -28% | -47% | 0% |
MOLECULAR PARTNERS AG |
MOLN |
7% | 20% | -39% | -66% | 0% |
Alzamend Neuro Inc. |
ALZN |
0% | 0% | -77% | -70% | 0% |
Janux Therapeutics Inc. |
JANX |
1% | 398% | -19% | -33% | 0% |
Centessa Pharmaceuticals plc |
CNTA |
2% | 110% | 157% | -73% | 0% |
Day One Biopharmaceuticals Holding Company LLC |
DAWN |
-1% | -13% | -32% | 28% | 0% |
Singular Genomics Systems Inc. |
OMIC |
0% | -39% | -77% | -83% | 0% |
Vera Therapeutics Inc. |
VERA |
2% | 175% | -21% | -28% | 0% |
Flora Growth Corp. |
FLGC |
0% | 0% | -19% | -87% | 0% |
Anebulo Pharmaceuticals Inc. |
ANEB |
-12% | -29% | 1% | -61% | 0% |
Talaris Therapeutics Inc. |
TALS |
0% | 0% | 167% | -93% | 0% |
Valneva SE |
VALN |
3% | -58% | -20% | -77% | 0% |
Vaccitech plc |
VACC |
0% | 0% | 0% | -78% | 0% |
Werewolf Therapeutics Inc. |
HOWL |
14% | -62% | 88% | -83% | 0% |
Impel NeuroPharma Inc. |
IMPL |
0% | 0% | -94% | -57% | 0% |
Rain Therapeutics Inc. |
RAIN |
0% | 1% | -85% | -38% | 0% |
Treace Medical Concepts Inc. |
TMCI |
6% | -42% | -45% | 23% | 0% |
NeuroPace Inc. |
NPCE |
4% | 9% | 592% | -84% | 0% |
Zymergen Inc. |
ZY |
0% | 0% | 0% | -63% | 0% |
Akoya Biosciences Inc. |
AKYA |
7% | -53% | -49% | -37% | 0% |
Biomea Fusion Inc. |
BMEA |
-4% | -73% | 72% | 13% | 0% |
Recursion Pharmaceuticals Inc. |
RXRX |
15% | -32% | 28% | -55% | 0% |
Reneo Pharmaceuticals Inc. |
RPHM |
0% | -8% | -31% | -73% | 0% |
Reneo Pharmaceuticals Inc. |
RPHM |
0% | -8% | -31% | -73% | 0% |
VectivBio Holding AG |
VECT |
0% | 0% | 96% | 75% | 0% |
Achilles Therapeutics plc |
ACHL |
-1% | 32% | -1% | -83% | 0% |
Design Therapeutics Inc. |
DSGN |
8% | 133% | -74% | -52% | 0% |
Edgewise Therapeutics Inc. |
EWTX |
4% | 144% | 22% | -42% | 0% |
Ikena Oncology Inc. (formerly KYN Therapeutics) |
IKNA |
3% | -17% | -26% | -79% | 0% |
LAVA Therapeutics BV |
LVTX |
9% | -39% | -55% | -36% | 0% |
Olink Holding AB |
OLK |
0% | 1% | -1% | 39% | 0% |
Movano Inc. |
MOVE |
0% | -57% | -40% | -66% | 0% |
Finch Therapeutics Group Inc. |
FNCH |
0% | 0% | -44% | -95% | 0% |
Instil Bio Inc. |
TIL |
0% | 0% | -50% | -96% | 0% |
BriaCell Therapeutics Corp. |
BCTX |
0% | 0% | 58% | -47% | 100% |
Virpax Pharmaceuticals Inc. |
VRPX |
0% | -3% | -49% | -82% | 0% |
Decibel Therapeutics Inc. |
DBTX |
0% | 0% | 140% | -57% | 0% |
Longeveron LLC |
LGVN |
0% | -75% | -58% | -73% | 0% |
Talis Biomedical Corporation |
TLIS |
0% | 0% | 12% | -89% | 0% |
Biophytis S.A. |
BPTS |
0% | 0% | 0% | -92% | 0% |
Vallon Pharmaceuticals Inc. |
VLON |
0% | 0% | 43% | -95% | 0% |
Evaxion Biotech A/S |
EVAX |
0% | -2% | -62% | -59% | 0% |
Immunocore Holdings Limited |
IMCR |
1% | -57% | 20% | 67% | 0% |
Cullinan Oncology LLC |
CGEM |
4% | 20% | -3% | -32% | 0% |
Inhibikase Therapeutics Inc. |
IKT |
0% | 0% | 22% | -66% | -79% |
908 Devices Inc. |
MASS |
4% | -80% | 47% | -71% | -55% |
BioAtla Inc. |
BCAB |
14% | -76% | -70% | -58% | -42% |
4D Molecular Therapeutic Inc. |
FDMT |
6% | -73% | -9% | 1% | -47% |
Vivos Therapeutics Inc. |
VVOS |
0% | 0% | -36% | -82% | -62% |
Seer Inc. |
SEER |
7% | 19% | -67% | -75% | -59% |
Sigilon Therapeutics Inc. |
SGTX |
0% | 0% | 43% | -87% | -94% |
Silverback Therapeutics Inc. |
SBTX |
0% | 0% | 0% | -30% | -85% |
SQZ Biotechnologies Company |
SQZ |
0% | 0% | -35% | -92% | -69% |
Abcam plc |
ABCM |
0% | 0% | 54% | -34% | 10% |
Aligos Therapeutics Inc. |
ALGS |
0% | -43% | -30% | -92% | -57% |
Kiromic Biopharma Inc. |
KRBP |
0% | 0% | -12% | -88% | -81% |
PRAXIS PRECISION MEDICINES INC. |
PRAX |
0% | 0% | -54% | -88% | -64% |
Aziyo Biologics Inc. |
AZYO |
-9% | 79% | -49% | -33% | -54% |
Pulmonx Corp. |
LUNG |
-4% | -47% | 51% | -74% | -53% |
Graybug Vision Inc. |
GRAY |
0% | 0% | -12% | -73% | -94% |
Greenwich LifeSciences Inc. |
GLSI |
14% | 7% | -31% | -38% | -28% |
PMV Pharmaceuticals Inc. |
PMVP |
3% | -51% | -64% | -62% | -61% |
Prelude Therapeutics Incorporated |
PRLD |
8% | -70% | -29% | -51% | -83% |
Taysha Gene Therapies Inc. |
TSHA |
10% | -2% | -22% | -81% | -54% |
Athira Pharma Inc. |
ATHA |
-6% | -76% | -23% | -76% | -61% |
COMPASS Pathways plc |
CMPS |
18% | -57% | 9% | -64% | -54% |
American Well Corp. |
AMWL |
0% | -75% | -47% | -53% | -76% |
Kymera Therapeutics Inc. |
KYMR |
3% | 58% | 2% | -61% | 2% |
Nano-X Imaging Ltd. |
NNOX |
28% | 13% | -14% | -49% | -68% |
Harmony Biosciences Holdings Inc. |
HRMY |
1% | 7% | -41% | 28% | 19% |
Inhibrx Inc. |
INBX |
0% | -10% | 54% | -44% | 32% |
Freeline Therapeutics Holdings plc |
FRLN |
0% | 0% | -50% | -75% | -89% |
AlloVir Inc. |
ALVR |
5% | -38% | -87% | -61% | -67% |
Annexon Inc. |
ANNX |
-2% | 13% | -12% | -55% | -54% |
Inozyme Pharma Inc. |
INZY |
10% | -35% | 306% | -85% | -67% |
iTeos Therapeutics Inc. |
ITOS |
6% | -30% | -44% | -58% | 38% |
Nurix Therapeutics Inc. |
NRIX |
4% | 83% | -6% | -62% | -12% |
Relay Therapeutics Inc. |
RLAY |
7% | -63% | -26% | -53% | -24% |
Poseida Therapeutics Inc. |
PSTX |
-1% | 186% | -37% | -25% | -36% |
Akouos Inc. |
AKUS |
0% | 0% | 0% | 56% | -57% |
Fusion Pharmaceuticals Inc. |
FUSN |
0% | 122% | 205% | -24% | -65% |
PolyPid Ltd. |
PYPD |
5% | -24% | 444% | -88% | -41% |
Forma Therapeutics Holdings Inc. |
FMTX |
0% | 0% | 0% | 40% | -61% |
Genetron Holdings Limited |
GTH |
0% | 0% | 4% | -82% | -56% |
Repare Therapeutics inc. |
RPTX |
6% | -82% | -50% | -30% | -39% |
Royalty Pharma plc |
RPRX |
1% | -9% | -29% | -1% | -20% |
Avidity Biosciences Inc. |
RNA |
5% | 222% | -59% | -7% | -11% |
Applied Molecular Transport Inc. |
AMTI |
0% | 0% | -35% | -97% | -58% |
Pliant Therapeutics Inc. |
PLRX |
3% | -27% | -6% | 43% | -40% |
Inari Medical Inc. |
NARI |
-3% | -21% | 2% | -32% | 7% |
ADC Therapeutics SA |
ADCT |
1% | 20% | -57% | -82% | -35% |
Ayala Pharmaceuticals Inc. |
AYLA |
0% | 0% | 27% | -95% | -23% |
Lyra Therapeutics Inc. |
LYRA |
1% | -96% | 67% | -28% | -62% |
ORIC Pharmaceuticals Inc. |
ORIC |
6% | -12% | 56% | -60% | -56% |
Keros Therapeutics Inc. |
KROS |
-1% | -60% | -17% | -18% | -15% |
Zentalis Pharmaceuticals LLC |
ZNTL |
7% | -80% | -25% | -76% | 62% |
IMARA Inc. |
IMRA |
0% | 0% | 55% | 81% | -90% |
Monopar Therapeutics Inc. |
MNPR |
0% | 121% | -86% | -26% | -48% |
Revolution Medicines Inc. |
RVMD |
1% | 52% | 20% | -5% | -36% |
Beam Therapeutics Inc. |
BEAM |
2% | -9% | -30% | -51% | -2% |
Arcutis Biotherapeutics Inc. |
ARQT |
5% | 331% | -78% | -29% | -28% |
Black Diamond Therapeutics Inc. |
BDTX |
3% | -24% | 56% | -67% | -83% |
Annovis Bio Inc. |
ANVS |
8% | -73% | 41% | -24% | 133% |
89bio Inc. |
ETNB |
2% | -30% | -12% | -1% | -47% |
CNS Pharmaceuticals Inc. |
CNSP |
0% | -84% | -48% | 242% | -61% |
Galera Therapeutics Inc. |
GRTX |
0% | 32% | -90% | -68% | -56% |
Oyster Point Pharma Inc. |
OYST |
0% | 0% | 0% | -39% | -3% |
RAPT Therapeutics Inc. |
RAPT |
5% | -94% | 26% | -46% | 86% |
Cabaletta Bio Inc. |
CABA |
5% | -90% | 145% | 144% | -70% |
Phathom Pharmaceuticals Inc. |
PHAT |
-5% | -11% | -19% | -43% | -41% |
TFF Pharmaceuticals Inc. |
TFFP |
0% | 0% | -70% | -88% | -38% |
Innate Pharma SA |
IPHA |
4% | -36% | -25% | -18% | 11% |
Vir Biotechnology Inc. |
VIR |
2% | -27% | -60% | -40% | 58% |
BioNTech SE |
BNTX |
2% | 8% | -30% | -42% | 216% |
Aprea Therapeutics Inc. |
APRE |
0% | 0% | 47% | -89% | -40% |
Frequency Therapeutics Inc. |
FREQ |
0% | 0% | -92% | -25% | -85% |
IGM Biosciences Inc. |
IGMS |
7% | -26% | -51% | -42% | -67% |
Satsuma Pharmaceuticals Inc. |
STSA |
0% | 0% | 22% | -80% | -2% |
SpringWorks Therapeutics Inc. |
SWTX |
6% | -1% | 40% | -58% | -15% |
Castle Biosciences Inc. |
CSTL |
7% | 24% | -8% | -47% | -34% |
Fulcrum Therapeutics Inc. |
FULC |
8% | -30% | -7% | -59% | 54% |
Genmab A/S |
GMAB |
3% | -34% | -25% | 6% | -2% |
Mirum Pharmaceuticals Inc. |
MIRM |
3% | 40% | 51% | 22% | -10% |
Karuna Therapeutics Inc. |
KRTX |
0% | 4% | 61% | 50% | 29% |
Xtant Medical Holdings Inc |
XTNT |
28% | 0% | 0% | -4% | -53% |
Protalix BioTherapeutics Inc |
PLX |
14% | 0% | 0% | 41% | -77% |
Cel Sci Corporation |
CVM |
7% | 0% | 0% | -66% | -39% |
BioTime Inc |
BTX |
0% | 0% | 0% | -93% | -4% |
Vericel Corporation |
VCEL |
4% | 54% | 35% | -33% | 27% |
VBI Vaccines Inc |
VBIV |
0% | 0% | -60% | -84% | -14% |
Vaxart Inc |
VXRT |
27% | 14% | -40% | -85% | 10% |
Titan Pharmaceuticals Inc |
TTNP |
0% | 7% | -47% | -23% | -69% |
Seattle Genetics Inc |
SGEN |
0% | 0% | 78% | -17% | -12% |
Sangamo Therapeutics Inc |
SGMO |
30% | 86% | -83% | -58% | -52% |
Repligen Corporation |
RGEN |
4% | -20% | 6% | -36% | 38% |
Qiagen N.V. |
QGEN |
0% | 1% | -13% | -10% | 5% |
PolarityTE Inc |
PTE |
0% | 0% | -63% | 13% | -15% |
Pluristem Therapeutics Inc |
PSTI |
0% | 0% | 0% | -51% | -79% |
Outlook Therapeutics Inc |
OTLK |
0% | -18% | -64% | -21% | 5% |
Organovo Holdings Inc |
ONVO |
1% | -61% | -22% | -61% | -70% |
Novavax Inc |
NVAX |
10% | 67% | -53% | -93% | 28% |
Neurocrine Biosciences Inc |
NBIX |
1% | 4% | 10% | 40% | -11% |
NanoString Technologies Inc |
NSTG |
0% | -86% | -91% | -81% | -37% |
Moderna Inc |
MRNA |
1% | -58% | -45% | -29% | 143% |
Microbot Medical Inc |
MBOT |
90% | -32% | -46% | -60% | 9% |
Iovance Biotherapeutics Inc |
IOVA |
3% | -9% | 27% | -68% | -57% |
Idera Pharmaceuticals Inc |
IDRA |
0% | 0% | 21% | -40% | -85% |
Heska Corporation |
HSKA |
0% | 0% | 93% | -66% | 25% |
Halozyme Therapeutics Inc |
HALO |
6% | 29% | -35% | 42% | -6% |
Gilead Sciences Inc |
GILD |
-1% | 14% | -6% | 18% | 25% |
Genetic Technologies Ltd |
GENE |
0% | 0% | -40% | -52% | -47% |
Fennec Pharmaceuticals Inc |
FENC |
-3% | -44% | 17% | 118% | -41% |
Fate Therapeutics Inc |
FATE |
9% | -56% | -63% | -84% | -32% |
Erytech Pharma S A |
ERYP |
0% | 0% | 39% | -86% | -74% |
Entera Bio Ltd |
ENTXW |
0% | 0% | 0% | -89% | 72% |
Eiger BioPharmaceuticals Inc |
EIGR |
0% | -3% | -81% | -77% | -58% |
CytRx Corporation |
CYTR |
0% | 0% | 0% | -79% | -70% |
Curis Inc |
CRIS |
0% | 0% | -31% | -88% | -42% |
Compugen Ltd |
CGEN |
5% | -23% | 177% | -83% | -64% |
Champions Oncology Inc |
CSBR |
14% | 57% | 20% | -45% | -24% |
CASI Pharmaceuticals Inc |
CASI |
0% | 0% | -9% | 126% | -73% |
Brainstorm Cell Therapeutics Inc |
BCLI |
0% | 18% | -83% | -61% | -8% |
bluebird bio Inc |
BLUE |
0% | -67% | -80% | -30% | -77% |
Bio Techne Corp |
TECH |
3% | -7% | -7% | -84% | 63% |
Biogen Inc |
BIIB |
-0% | -41% | -7% | 15% | -2% |
BioCryst Pharmaceuticals Inc |
BCRX |
2% | 25% | -48% | -18% | 88% |
argenx SE |
ARGX |
1% | 62% | 0% | 8% | 19% |
Aptose Biosciences Inc |
APTO |
0% | 0% | -26% | -57% | -69% |
Amgen Inc |
AMGN |
0% | -10% | 10% | 16% | -2% |
Agenus Inc |
AGEN |
0% | -46% | -66% | -25% | 1% |
Aerie Pharmaceuticals Inc |
AERI |
0% | 0% | 0% | 112% | -47% |
Adverum Biotechnologies Inc |
ADVM |
0% | 102% | 30% | -67% | -84% |
ADMA Biologics Inc |
ADMA |
7% | 279% | 16% | 176% | -28% |
Acorda Therapeutics Inc |
ACOR |
0% | 0% | -35% | -68% | 208% |
Solid Biosciences Inc. |
SLDB |
3% | -35% | 14% | 207% | -77% |
Surface Oncology Inc. |
SURF |
0% | 0% | 30% | -83% | -48% |
Scholar Rock Holding Corporation |
SRRK |
4% | 130% | 108% | -63% | -49% |
MeiraGTx Holdings plc |
MGTX |
5% | -13% | 8% | -73% | 57% |
AVROBIO Inc. |
AVRO |
0% | 4% | 91% | -81% | -72% |
Autolus Therapeutics plc |
AUTL |
14% | -64% | 239% | -63% | -42% |
Entera Bio Ltd. |
ENTX |
29% | 250% | -18% | -74% | 161% |
Rubius Therapeutics Inc. |
RUBY |
0% | 0% | -52% | -98% | 28% |
Replimune Group Inc. |
REPL |
4% | 44% | -69% | 0% | -31% |
Liquidia Technologies Inc. |
LQDA |
4% | -2% | 89% | 31% | 65% |
Sutro Biopharma Inc. |
STRO |
6% | -57% | -47% | -46% | -31% |
Gritstone Oncology Inc. |
GRTS |
0% | -65% | -41% | -73% | 226% |
Kodiak Sciences Inc |
KOD |
-8% | 228% | -58% | -92% | -42% |
Allogene Therapeutics Inc. |
ALLO |
1% | -33% | -49% | -58% | -41% |
LogicBio Therapeutics Inc. |
LOGC |
0% | 0% | 0% | -88% | -70% |
Gamida Cell Ltd. |
GMDA |
0% | -89% | -68% | -49% | -70% |
Twist Bioscience Corporation |
TWST |
4% | 26% | 55% | -69% | -45% |
Orchard Therapeutics plc |
ORTX |
0% | 0% | 44% | -72% | -69% |
Jounce Therapeutics Inc. |
JNCE |
0% | 0% | 69% | -87% | 28% |
Krystal Biotech Inc. |
KRYS |
1% | 26% | 57% | 13% | 15% |
Allena Pharmaceuticals Inc. |
ALNA |
0% | 0% | 0% | -90% | -54% |
Denali Therapeutics Inc. |
DNLI |
4% | -5% | -23% | -38% | -47% |
Editas Medicine Inc. |
EDIT |
4% | -87% | 14% | -67% | -62% |
CRISPR Therapeutics AG |
CRSP |
4% | -37% | 54% | -46% | -51% |
TRACON Pharmaceuticals Inc. |
TCON |
0% | -5% | -88% | -46% | -76% |
Cellectis S.A. |
CLLS |
-8% | -41% | 47% | -74% | -70% |
Cidara Therapeutics Inc. |
CDTX |
0% | -12% | 5% | -42% | -35% |
Adaptimmune Therapeutics plc |
ADAP |
21% | -33% | -46% | -61% | -31% |
aTyr Pharma Inc. |
LIFE |
10% | 157% | -36% | -71% | 95% |
BiondVax Pharmaceuticals Ltd. |
BVXV |
0% | -26% | -80% | 26% | -17% |
REGENXBIO Inc. |
RGNX |
1% | -57% | -21% | -31% | -28% |
Voyager Therapeutics Inc. |
VYGR |
6% | -33% | 38% | 125% | -62% |
Mesoblast Limited |
MESO |
0% | -5% | -62% | -40% | -43% |
Genocea Biosciences Inc. |
GNCA |
0% | 0% | 0% | -100% | -54% |
Applied Genetic Technologies Corporation |
AGTC |
0% | 0% | 0% | -79% | -54% |
Atara Biotherapeutics Inc. |
ATRA |
0% | -23% | -84% | -79% | -20% |
DBV Technologies S.A. |
DBVT |
0% | -40% | -38% | -7% | -37% |
Coherus BioSciences Inc. |
CHRS |
21% | -59% | -58% | -50% | -8% |